Filing Details
- Accession Number:
- 0000899243-22-030515
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-09-06 20:50:20
- Reporting Period:
- 2022-09-01
- Accepted Time:
- 2022-09-06 20:50:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1088856 | Corcept Therapeutics Inc | CORT | Pharmaceutical Preparations (2834) | 770487658 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1698310 | Sean Maduck | C/O Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park CA 94025 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-09-01 | 25,000 | $3.29 | 79,618 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-09-01 | 25,000 | $25.84 | 54,618 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-09-01 | 922 | $25.98 | 55,540 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2022-09-01 | 922 | $0.00 | 56,462 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2022-09-01 | 25,000 | $0.00 | 15,000 | $3.29 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 82,602 | 2025-02-18 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 10,000 | Indirect | See Footnote |
| Common Stock | 10,000 | Indirect | See Footnote |
Footnotes
- The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.82 to $25.94. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022.
- In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan.
- Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.
- Fully exercisable.
Billionaire Hedge Funds
